Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASLAN003 in Healthy Elderly Subjects
NCT02342652Phase 1Completed
- Sponsor
- ASLAN Pharmaceuticals
- Start
- Oct 2014
- Primary completion
- Mar 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial in acute myeloid leukemia (AML) comparing ASLAN003 with Placebo (2 arms). Primary endpoints: Safety at 6 months and Pharmacokinetics at Day 19. Started Oct 2014; status: completed.
02
Drugs
farudodstat
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT02342652.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02342652.